Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903498 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4EPOLBGAAAKT1 | |
| SCHEMBL4891405 | 0.95 | AKT1 (0.41) | ALDH1A1GAAAKT1CDK2NAMPT | |
| SCHEMBL4896077 | 0.95 | AKT1 (0.41) | ALDH1A1GAAAKT1CDK2NAMPT | |
| SCHEMBL4781246 | 0.95 | AKT1 (0.41) | ALDH1A1GAAAKT1CDK2NAMPT | |
| SCHEMBL4899142 | 0.93 | AKT1 (0.41) | ALDH1A1AKT1CDK2NAMPT | |
| SCHEMBL4900162 | 0.93 | AKT1 (0.41) | ALDH1A1AKT1CDK2NAMPT | |
| SCHEMBL4898951 | 0.90 | AKT1 (0.41) | ALDH1A1KDM4EAKT1 | |
| SCHEMBL4899055 | 0.90 | GAA (0.41) | ALDH1A1KDM4EGAAAKT1 | |
| SCHEMBL4904361 | 0.90 | AKT1 (0.41) | ALDH1A1KDM4EPOLBGAAAKT1 | |
| SCHEMBL4901998 | 0.90 | AKT1 (0.41) | ALDH1A1KDM4EPOLBGAAAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, MTOR | ALDH1A1 1752/4885KDM4E 1212/4885POLB 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.